To compare the reversal of vecuronium induced neuromuscular blockade using sugammadex 100mg and neostigmine 2.5mg in surgery under general anaesthesia.

Comparison of reversal of vecuronium induced neuromuscular blockade using sugammadex 100mg and neostigmine 2.5mg in surgery under general anaesthesia. - Nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/09/095229

Enrollment

Registered

2025-09-22

Start date

Unknown

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M279- Disease of jaws, unspecified Health Condition 2: Z00-Z99- Factors influencing health status and contact with health services Health Condition 3: O- Medical and Surgical Health Condition 4: M958- Other specified acquired deformities of musculoskeletal system

Interventions

Intervention1: Inj. Neostigmine 2.5mg: Neostigmine is a quaternary ammonium compound with a strong alkaline carbamoyl group. Neostigmine binds to the anion site of acetylcholinesterase and is then tra

Eligibility

Inclusion criteria

Inclusion criteria: ASA I,II, III Patients willing to participate in the study Prolonged duration surgery under general anaesthesia for more than four hours. Preoperative oxygen saturation of 98-100 percent on room air.

Exclusion criteria

Exclusion criteria: Lack of valid informed written consent. ASA grade IV. Patients with bleeding disorders. Patients on anticoagulants. Allergies to food and drugs. Patients with cardiac, renal, hepatic and respiratory co-morbidities. Patients on medication known to interact with neuromuscular blocking drugs e.g.: Antibiotics (aminoglycosides, tetracycline), antidepressants, anticonvulsants, antiarrhythmics (calcium channel blockers and quinidine) and magnesium sulphate and patients with known allergy to cisatracurium.

Design outcomes

Primary

Measure	Time frame
To compare the time of complete recovery (TOF=0.9) from vecuronium induced shallow neuromuscular blockade following administration of sugammadex 100mg with neostigmine 2.5mg on reversal to muscle relaxant.Timepoint: 2 hours	—

Secondary

Measure	Time frame
1. To compare the number of patients requiring top-up doses of respective reversal agent to reach a Train-of-Four (TOF) ratio of more than equal to 0.9 in both groups. 2 . To compare the incidence of residual neuromuscular blockade, recurarization and any adverse effects associated between two groups. 3. To compare hemodynamic effects (e.g., heart rate, blood pressure) following administration of each dose.Timepoint: 2 hours	—

Measure

Time frame

1. To compare the number of patients requiring top-up doses of respective reversal agent to reach a Train-of-Four (TOF) ratio of more than equal to 0.9 in both groups. 2 . To compare the incidence of residual neuromuscular blockade, recurarization and any adverse effects associated between two groups. 3. To compare hemodynamic effects (e.g., heart rate, blood pressure) following administration of each dose.Timepoint: 2 hours

—

Countries

India

Contacts

Public ContactDr Sanjot Ninave

Datta meghe institute of higher education and research

drsusann02@rediffmail.com9921213404

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026